- Home
- ALXO vs ADVB Comparison
ALXO vs ADVB Comparison
Compare ALXO & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- ADVB
- Stock Information
- Founded
- ALXO 2015
- ADVB 2014
- Country
- ALXO United States
- ADVB United States
- Employees
- ALXO N/A
- ADVB N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- ADVB Medical Specialities
- Sector
- ALXO Health Care
- ADVB Health Care
- Exchange
- ALXO Nasdaq
- ADVB Nasdaq
- Market Cap
- ALXO 76.5M
- ADVB 79.0M
- IPO Year
- ALXO 2020
- ADVB 2025
- Fundamental
- Price
- ALXO $0.66
- ADVB $4.00
- Analyst Decision
- ALXO Strong Buy
- ADVB
- Analyst Count
- ALXO 6
- ADVB 0
- Target Price
- ALXO $4.14
- ADVB N/A
- AVG Volume (30 Days)
- ALXO 1.4M
- ADVB 126.8K
- Earning Date
- ALXO 03-06-2025
- ADVB 01-01-0001
- Dividend Yield
- ALXO N/A
- ADVB N/A
- EPS Growth
- ALXO N/A
- ADVB N/A
- EPS
- ALXO N/A
- ADVB N/A
- Revenue
- ALXO N/A
- ADVB N/A
- Revenue This Year
- ALXO N/A
- ADVB N/A
- Revenue Next Year
- ALXO N/A
- ADVB N/A
- P/E Ratio
- ALXO N/A
- ADVB N/A
- Revenue Growth
- ALXO N/A
- ADVB N/A
- 52 Week Low
- ALXO $0.65
- ADVB $3.06
- 52 Week High
- ALXO $17.83
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- ALXO 33.23
- ADVB N/A
- Support Level
- ALXO $0.65
- ADVB N/A
- Resistance Level
- ALXO $0.74
- ADVB N/A
- Average True Range (ATR)
- ALXO 0.07
- ADVB 0.00
- MACD
- ALXO -0.00
- ADVB 0.00
- Stochastic Oscillator
- ALXO 0.54
- ADVB 0.00
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.